Sanofi-Aventis (New York) (SAN.PA) And Bristol-Myers Squibb Company (BMY) Release: Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
11/6/2008 11:29:10 AM
PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix® (clopidogrel bisulfate) and aspirin on cardiovascular outcomes and bleeding complications in patients with acute coronary syndrome (ACS) who are intended to undergo intervention with coronary angioplasty.
|